

1 **Development of a Rapid Point-Of-Care Test that Measures Neutralizing Antibodies to**
2 **SARS-CoV-2**

3 Douglas F. Lake^{1*#}, Alexa J. Roeder^{1*}, Erin Kaleta², Paniz Jasbi³, Sivakumar Periasamy^{4,5}
4 Natalia Kuzmina^{4,5} Alexander Bukreyev^{4,5,6}, Thomas Grys², Liang Wu⁷, John R Mills⁷, Kathrine
5 McAulay², Maria Gonzalez-Moa⁸, Alim Seit-Nebi⁸, and Sergei Svarovsky⁸

6
7 Affiliations:

- 8 1. School of Life Sciences, Arizona State University, Tempe AZ, USA
- 9 2. Mayo Clinic Arizona, Department of Laboratory Medicine and Pathology, Scottsdale, AZ,
10 USA
- 11 3. College of Health Solutions, Arizona State University, Phoenix AZ, USA
- 12 4. Department of Pathology, University of Texas Medical Branch at Galveston, Galveston,
13 TX USA
- 14 5. Galveston National Laboratory, University of Texas Medical Branch at Galveston,
15 Galveston, TX USA
- 16 6. Department of Microbiology and Immunology University of Texas Medical Branch at
17 Galveston, Galveston, TX USA
- 18 7. Mayo Clinic Rochester, Department of Laboratory Medicine and Pathology, Rochester,
19 MN USA
- 20 8. Axim Biotechnologies Inc, San Diego, CA USA

21 *Co-first authors

22
23 Running Head: Rapid Neutralization Test for COVID-19

24 #Address correspondence to Douglas F. Lake, douglas.lake@asu.edu

25
26 Douglas F Lake and Alexa J Roeder contributed equally to this work. Author order was
27 determined on the basis of seniority

28
29
30

31

32 **Abstract:**

33 As increasing numbers of people recover from and are vaccinated against COVID-19, tests are
34 needed to measure levels of protective, neutralizing antibodies longitudinally to help determine
35 duration of immunity. We developed a lateral flow assay (LFA) that measures levels of
36 neutralizing antibodies in plasma, serum or whole blood. The LFA is based on the principle that
37 neutralizing antibodies inhibit binding of the spike protein receptor-binding domain (RBD) to
38 angiotensin-converting enzyme 2 (ACE2). The LFA compares favorably with authentic SARS-
39 CoV-2 and pseudotype neutralization assays with an accuracy of 98%. Sera obtained from
40 patients with seasonal coronaviruses did not prevent RBD from binding to ACE2. To
41 demonstrate the usefulness of the LFA for measuring antibodies in convalescent plasma used
42 for therapy, we measured conversion of non-immune plasma into strongly neutralizing plasma.
43 This is the first report of a neutralizing antibody test that is rapid, highly portable and relatively
44 inexpensive that might be useful in assessing COVID-19 vaccine-induced immunity.

45

46

47 **Introduction**

48 The pandemic virus, Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2)
49 continues to be transmitted by person to person spread from its origin in Wuhan, China in
50 December 2019(1–3) . Vaccine trials are ongoing, and preliminary results from at least 2
51 vaccines show that the vaccines elicit protective immunity, but durability of vaccine responses is
52 not known(4).

53

54

55

56

57

Molecular tests such as PCR detect SARS-CoV-2 nucleic acid in nasopharyngeal secretions and saliva and are diagnostic of infection(5). These molecular tests can determine the rate of infection and potential re-infection. When negative they indicate that patients have cleared the virus. In response to infection, all immunocompetent hosts generate antibodies against the virus. Patients may have a positive serologic test result as well as a PCR-positive

58 test result if they are early in convalescence(6). For SARS-CoV-2, antibodies to spike protein
59 do not always predict recovery from COVID-19(7).

60 Although immunocompetent individuals infected with SARS-CoV-2 generate antibodies
61 against the virus, it is essential to know which individuals generate high levels of neutralizing
62 antibodies (NAbs) so that they can resume normal activities without fear of being re-infected
63 and spreading the virus to others(8–10). The goal of COVID-19 vaccines is to induce NAbs and
64 T cell responses that prevent infection/re-infection. Additionally, development of NAbs indicates
65 which individuals might be optimal donors for convalescent plasma protocols. Although NAbs
66 are important for elimination of the virus and protection from subsequent infection, it has been
67 reported by several groups that up to one-third of convalescent plasma samples from individuals
68 who have recovered from COVID-19 do not neutralize SARS-CoV-2 or spike pseudotype virus
69 infection(11–13).

70 Viral neutralization assays measure levels of antibodies that block infection of host cells.
71 Two main types of viral neutralization assays are utilized for SARS-CoV-2. Authentic
72 microneutralization assays measure reduction of viral plaques or infectious foci in
73 microneutralization assays in susceptible host cells using SARS-CoV-2 under BSL3 conditions.
74 These assays are slow, laborious, require highly trained personnel and require a BSL3 facility.
75 Pseudotype virus neutralization assays have been developed in which SARS-CoV-2 spike
76 protein is expressed in a virus such as vesicular stomatitis virus or lentivirus(14, 15). These
77 assays are faster and less dangerous than authentic microneutralization assays, but still require
78 BSL2 conditions and 24-48 hours for results. Another challenge is that both authentic and
79 pseudovirus virus neutralization assays depend on host cells for infection which adds variability
80 to the assay.

81 It is known that SARS-CoV-2 uses receptor binding domain (RBD) on spike protein to
82 bind angiotensin converting enzyme 2 (ACE2) on host cells; this appears to be the principal

83 neutralizing domain of SARS-CoV-2(16, 17). Using this knowledge, we developed a lateral flow
84 assay (LFA) that measures levels of (neutralizing) antibodies which block RBD from binding to
85 ACE2. Other groups have developed RBD-ACE2-based competition ELISAs(18)-(19) but none
86 have developed a rapid, highly portable semi-quantitative point-of-care (POC) test.

87

88 **Methods**

89 *Human Subjects and Samples*

90 Peripheral blood, serum and plasma were collected for this study under an Arizona State
91 University institutional review board (IRB) approved protocol #0601000548 and Mayo Clinic IRB
92 protocol #20-004544. Plasma was obtained by ficoll gradient separation of peripheral blood and
93 serum was obtained by centrifugation 30 minutes after drawing blood. Plasma and serum
94 samples obtained from excess clinical samples at Mayo Clinic were pre-existing, de-identified
95 and leftover from normal workflow. COVID-19 samples ranged from 3 to 84 days post PCR
96 positive result. Residual clinical samples were stored at 2-8°C for up to 7 days, and frozen at
97 -80°C thereafter.

98 Serum samples from patients with non-COVID-19 respiratory illnesses were also tested.
99 These specimens were collected from patients from 2/14/17 – 4/6/20 and were tested by the
100 FilmArray Respiratory Panel 2 (RP2) (Biofire Diagnostics, Salt Lake City, UT) respiratory virus
101 panel as part of routine clinical workflow. Specimens were stored at -80°C until analysis.

102

103 *Pseudotype Virus Neutralization Assays*

104 Titers were obtained from 60 COVID-19 patient sera using a vesicular stomatitis virus (VSV)
105 spike protein pseudotype assay as previously reported with modifications (14). Patient sera had
106 been stored at -80°C prior to testing. Briefly, SARS-CoV-2 pseudotypes were created by
107 replacing VSV G glycoprotein with SARS-CoV-2 spike protein resulting in a pseudotyped virus
108 with the C-terminal 19 amino acids removed from spike. The pseudotyped virus is called VSV-

109 SARS-CoV-2-S-Δ19CT and was produced by BHK-21 cells. It induces syncytium formation
110 when incubated with vero cells. Two different Vero cells encoding split product luciferase
111 (DSP1 and DSP2) were cultured at a 1:1 ratio as a monolayer. Virus-induced fusion leads
112 to luciferase complementation and in the presence of luciferase substrate
113 EnduRen™ (Promega, Madison, WI) generates luminescence. The higher luminescence, the
114 more infection events by the virus. A human monoclonal antibody (Regeneron, Tarrytown,
115 NY) targeting the SARS-CoV-2 spike protein was diluted to set a cut-off at 50% neutralizing
116 activity and utilized as a single point calibrator. Patient sera with serial dilutions (1:80-
117 1:2560) and the calibrator were pre-incubated with virus for 30 minutes (neutralization) prior to
118 addition to DSP1 and DSP2 Vero cells. The virus-cell mixture was incubated at 37°C in a 5%
119 CO₂ incubator for a total of 24 hours before luminescence reading; the substrate
120 EnduRen™ was added at 18 hours of incubation. The raw luminescence signal of each sera
121 dilution was compared against the raw luminescence signal of the calibrator. The
122 last consecutive dilution with luminescence signal below the calibrator was considered the end-
123 point titer. Samples were tested in duplicate. The same serum samples, 68 coded sera (10
124 serum samples at titers of 1:80, 1:160, 1:320, 1:640, 1:1280, 1:2560 and 8 serum samples from
125 individuals never infected with COVID-19) were frozen at -20°C and shipped by Dr. Mills from
126 Mayo Clinic Rochester to Mayo Clinic Arizona and the Lake Lab for LFA testing.

127

128 *Authentic SARS-CoV-2 Microneutralization Assay*

129 The authentic microneutralizing assay was performed using a recombinant SARS-CoV-2 that
130 expresses mNeonGreen (SARS-CoV-2ng) during replication in permissive cells, as previously
131 described (20). Inhibitory concentrations for which 50% of virus is neutralized by serum
132 antibodies (IC₅₀ values) were obtained on a unique set of 38 COVID-19 sera. Sixty µl aliquots of
133 SARS-CoV-2ng were pre-incubated for 1 h in 5% CO₂ at 37°C with 60µl serial 2-fold serum

134 dilutions in cell culture media, and 100µl were inoculated into Vero-E6 monolayers in black
135 polystyrene 96-well plates with clear bottoms (Corning, Tewksbury, MA). Each serum was
136 tested in duplicates. The final amount of the virus was 200 PFU/well, and the starting serum
137 dilution was 1:20 and the end dilution was 1280 unless an IC₅₀ was not reached in which case
138 serum was diluted to 1:10240. Cells were maintained in Minimal Essential Medium
139 (ThermoFisher Scientific, Waltham, MA) supplemented by 2% FBS (HyClone, Logan, UT) and
140 0.1% gentamycin in 5% CO₂ at 37°C. After 2 days of incubation, fluorescence intensity of
141 infected cells was measured at a 488 nm wavelength using a Synergy 2 Cell Imaging Reader
142 (Biotek, Winooski, VT). The signal readout was normalized to virus control aliquots with no
143 serum added and was presented as the percentage of neutralization. IC₅₀ was calculated with
144 GraphPadPrism 6.0 software. Work with infectious SARS-CoV-2ng was performed in a BSL-3
145 biocontainment laboratory of the University of Texas Medical Branch, Galveston, Tx, Galveston
146 National Laboratory.

147

148 *Serologic Antibody Assay*

149 The Ortho Vitros Anti-SARS-CoV-2 IgG test was performed on the Ortho Clinical
150 Diagnostics Vitros 3600 Immunodiagnosics System (Ortho, Raritan, NJ) following
151 manufacturer's instructions at the Mayo Clinic. This assay is approved for use in clinical testing
152 under FDA Emergency Use Authorization to qualitatively detect antibody to the S1 subunit of
153 SARS-CoV-2 spike protein. Results are reported as reactive (S/CO ≥ 1.0) or Nonreactive (S/CO
154 <1.0). Quantitative results are not reported for clinical workflows but are measured and recorded
155 in this assay. Specimens were tested within 7 days of collection and were stored at 2-8°C per
156 manufacturer's instructions. This assay was performed after the VSV assay was performed on
157 the set of 60 serum samples, then the samples were frozen at -80°C before running them on the
158 LFA. A separate set of 38 samples was run concurrently in the SARS-CoV-2 authentic
159 microneutralizing antibody assay, the LFA, and the Ortho Vitros Anti-SARS-CoV-2 IgG assay.

160 *Lateral Flow Neutralizing Antibody Assay*

161 The Lateral Flow Neutralizing Antibody assay was developed to detect antibodies that
162 compete with ACE2 for binding to RBD. The LFA cassette contains a test strip composed of a
163 sample pad and blood filter, conjugate pad, nitrocellulose membrane striped with test and
164 control lines, and an absorbent pad to wick excess moisture (Axim Biotechnologies Inc, San
165 Diego, CA). The blood filter allows serum to pass through but prevents red blood cells and
166 leukocytes from interfering with the assay. Test strips are secured in a cassette that contains a
167 single sample port (Empowered Diagnostics, Pompano Beach, FL). For procedural control
168 purposes, the LFA also contains a control mouse antibody conjugated to red gold nanospheres
169 and corresponding anti-mouse control line.

170 LFAs were performed at ambient temperature and humidity on a dry, flat surface and left
171 to run undisturbed for 10 minutes prior to reading results. First, 10 μ l of plasma, serum or whole
172 blood were transferred to the cassette sample port and immediately followed by two drops
173 (~50 μ l) of chase buffer. After 10 minutes, each test was placed in an iDetekt RDS-2500 LFA
174 reader (Austin, TX) and the densities of both test and control lines were recorded electronically.
175 This assay was performed on the VSV subset (n = 60) as well as the authentic SARS-CoV-2
176 microneutralizing antibody assay subset (n = 38).

177 Serum samples from COVID-19 patients as well as sera from patients with PCR-
178 confirmed seasonal respiratory viruses including PCR-confirmed seasonal coronaviruses were
179 tested in the LFA as controls. Twenty-seven sera from patients with seasonal respiratory
180 viruses were tested in the LFA in a manner identical to COVID-19 sera.

181 The test leverages the interaction between RBD-conjugated green-gold nanoshells
182 (Nanocomposix, San Diego, CA) that bind ACE2 at the test line when RBD-binding/neutralizing

183 antibodies (RBD-NAbs) are absent or low. As indicated by the competitive nature of this assay,
184 test line density is inversely proportional to RBD-NAbs present within the sample. Thus, an
185 absent or faint test line indicates high levels of RBD-NAbs, whereas a dark or strong test line
186 suggests lack of RBD-NAbs within a given plasma sample (Figure 1A).

187 As a semi-quantitative test, the results of the LFA can be interpreted using a scorecard
188 or a densitometer. Figure 1B demonstrates the scorecard. Red control line across from the “C”
189 on the cassette is composed of a mouse monoclonal antibody coupled to red-gold beads
190 binding to an anti-mouse IgG. A red line indicates that the test ran properly and the green test
191 line across from the “T” can be used to semi-quantitatively measure the ability of plasma, serum
192 or whole blood to block RBD on green-gold nanoshells from binding to ACE2.

193 To demonstrate the ability of the test to measure NAbs in whole blood, 10 μ g of a
194 neutralizing monoclonal antibody (mAb) based on the sequence of B-38(20)(Axim
195 Biotechnologies, Inc, San Diego, CA) was mixed with 10 μ l of normal donor whole blood
196 collected in a heparinized blood collection tube. Two-fold dilutions were made in whole blood to
197 a final concentration of 0.625 μ g/ml neutralizing mAb. Then, 10 μ l of each dilution were
198 transferred to LFA cassettes, chased with 50 μ l running buffer, and read with an LFA reader after
199 10 minutes.

200

201 *Conversion of Non-immune Normal Human Plasma (NIHP) into Neutralizing Plasma*

202 To convert NIHP into strongly neutralizing plasma (SNP), plasma from a convalescent
203 donor who demonstrated the ability to block RBD from binding to ACE2 (M21) was mixed with
204 NIHP collected prior to December 2019. For example, for a 1% mixture, 1 μ l of SNP was mixed
205 with 99 μ l NIHP; for a 5% mixture 5 μ l of SNP was admixed with 95 μ l NIHP, etc. We performed
206 the test with 10 μ l of 1%, 5%, 10%, and 20% SNP admixed into NIHP.

207

208 *Data Analysis*

209 Pearson's correlation (r) was conducted to assess the strength and significance of
210 associations between the LFA, the Ortho Vitros Anti-SARS-CoV-2 IgG test, VSV titers and IC_{50}
211 values. Regression analysis using IC_{50} values was performed to evaluate consistency(18) while
212 Bland-Altman plots were constructed to assess agreement and bias(21, 22). Correlation analysis
213 was conducted using IBM SPSS (Armonk, NY). Regression analysis was performed using
214 Microsoft Excel (Redmond, WA); Bland-Altman plots were visualized using IBM SPSS. For two-
215 group analysis, IC_{50} values corresponding to >240 were categorized as titer of $\geq 1:320$
216 (neutralizing), whereas IC_{50} values ≤ 240 were categorized as $\leq 1:160$ (non-neutralizing). Receiver
217 operating characteristic (ROC) analysis was performed to assess classification accuracy,
218 sensitivity, and specificity of the LFA and Ortho Vitros Anti-SARS-CoV-2 IgG test methods in
219 assessing neutralizing capacity; optimal cutoffs for each method were established to maximize
220 area under curve (AUC)(23, 24). ROC analysis was conducted using R language in the RStudio
221 environment (version 3.6.2; RStudio PBC, Boston, MA). All analyses were conducted using raw
222 values; data were not normalized, transformed, or scaled.


223

224 **Results**

225 The lateral flow assay reported here is a rapid 10-minute POC test. As shown in the
226 schematic in **Figure 1A**, this test utilizes serum, plasma or whole blood to semi-quantitatively
227 measure levels of NABs. An example of strong, moderate and non-neutralizing sera is shown in
228 **Figure 1B**. As diagrammed in **Figure 1A**, levels of NABs in serum or plasma are reflected by
229 the intensity of the test line which can be read on a hand-held densitometer or compared
230 visually to a scorecard (**Figure 1B**). Strong neutralization results in a weak line because
231 neutralizing antibodies are binding RBD on green gold beads and preventing RBD-beads from
232 binding to the ACE2 cellular receptor at the test line.


233

234



235
236
237
238

239
240 Density Unit Range: <50,000 50,000-150,000 150,000-450,000 >450,000
241
242 Actual Line Density: 10095 132503 317156 645040




248 **Figure 1.**
249 **(A)** Schematic of Neutralization LFA. Below each graphic is a representative image of a lateral
250 flow strip demonstrating actual line density. Addition of non-COVID19-immune serum or plasma
251 (*top*) does not block binding of RBD-beads (green particles) to ACE2 resulting in the RBD-
252 bead–ACE2 complex creating a visible line. Addition of patient serum with moderate titer NAbs
253 to the sample pad creates a weak line (*middle*). Addition of patient serum with high titer NAbs
254 (> 1:640) blocks binding of RBD-beads to ACE2 such that no line is observed at the test
255 location on the strip (*bottom*). Red control line represents capture of a mouse monoclonal
256 antibody coupled to red beads. **(B)** Scorecard for measuring levels of NAbs. Red control line
257 across from the “C” on the cassette indicates that the test ran properly and the green test line
258 across from the “T” can be used to measure the ability of plasma or serum to block RBD on gold
259 nanoshells from binding to ACE2. **(0)** represents patient serum producing a visually non-existent
260 line with density units of 10,095 and an IC₅₀>500 (IC₅₀=1151); **(1)** represents patient serum with
261 a line density of 132,503 and an IC₅₀ of 396; **(2)** represents patient serum with a line density of
262 239,987 and an IC₅₀ of 243; **(3)** represents patient serum with a line density of 485,665 and an
263 IC₅₀ of 96.
264

265 We tested 60 serum samples with known neutralization titers obtained in a VSV-based
266 spike pseudotype assay in our LFA. De-identified serum samples were sent from Mayo Clinic
267 Rochester to our laboratories at Mayo Clinic Arizona and run in a blinded manner. The LFA
268 result compared favorably with serum titers, especially at higher titers and correctly
269 distinguished all eight non-neutralizing serum samples (**Figure 2A**).



270 To further support the application of our lateral flow test to measure levels of antibodies
271 that neutralize SARS-CoV-2, we tested a different set of 38 serum samples that were assigned
272 IC₅₀ values in an authentic SARS-CoV-2 microneutralization assay(25). Again, the experiment
273 was performed in a blinded manner such that personnel running either the LFA or the
274 microneutralization assay did not know the results of the comparator test. When line densities
275 from the LFA were plotted against IC₅₀ values determined in the SARS-CoV-2 microneutralization

276 assay, serum samples with strong neutralization activity demonstrated low line densities; this
277 indicates that neutralizing antibodies inhibited RBD from binding to ACE2 (**Figure 2B**).
278



279
280 **Figure 2. (A)** Comparison of RBD-ACE2 competition LFA Density Units with VSV-Spike
281 pseudotype virus assay titers using 60 convalescent serum samples. Titters from the
282 pseudotype assay are shown on the X-axis. Scatter plots with bar graph including standard
283 deviation of the mean for 10 serum samples at each titer except for negative donor serum which
284 is eight samples. **(B)** Comparison of RBD-ACE2 competition LFA with IC₅₀ values determined in
285 a SARS-CoV-2 microneutralization assay on 38 samples (collected 3 to 90 days after PCR
286 positive result). Ranges of IC₅₀ values are shown on the X-axis plotted against LFA line density
287 units on the Y-axis.
288


289 Next, we determined if our test detected any neutralization activity in serum samples
290 collected from patients with other PCR -confirmed respiratory viruses including seasonal
291 coronaviruses (**Figure 3A**) and for serum samples collected prior to December 2019 (**Figure**
292 **3B**). None of the seasonal respiratory virus plasma samples, including pre-December 2019
293 samples showed neutralizing activity.



296
297
298 **Figure 3. A)** Serum samples collected with PCR-confirmed diagnosis of seasonal respiratory
299 viruses (Coronavirus OC43, blue; Coronavirus HKU-1, green; Coronavirus NL-63, pink;
300 influenza A, orange, influenza B, red ; parainfluenza, purple ; rhinovirus, teal ; respiratory
301 syncytial virus, yellow ; and adenovirus, black) were run on the LFA as described in Methods.

302 A positive control serum from a convalescent COVID-19 patient is shown on the far right of the
303 bar graph in white. **B)** Serum samples collected pre-December 2019. Cutoff value of 263,000
304 density units was calculated based on receiver operating characteristic curves (see Figure 6).
305


306 We evaluated how the Ortho Vitros Anti-SARS-CoV-2 IgG test and our LFA compared to
307 IC_{50} values determined in an authentic SARS-CoV-2 microneutralization assay using 38 COVID-
308 19 sera. FDA guidance indicates that an Ortho Vitros Anti-SARS-CoV-2 IgG test of ≥ 12 meets a
309 threshold for convalescent plasma use in patients with COVID-19. To determine the agreement
310 between our lateral flow assay and the Ortho Vitros Anti-SARS-CoV-2 IgG test, density units from
311 our LFA and values from the Ortho test were regressed onto IC_{50} values (**Figure 4**).
312



313 **Figure 4.** Regression analysis between **(A)** LFA and serum titer, and **(B)** Ortho Vitros SARS-
314 CoV-2 IgG test and titer. Regression plots show explained variance (R^2) between compared
315 methods. Thirty-eight samples were tested.
316
317


318 LFA values accounted for roughly 52% of observed variance in IC_{50} values, while Ortho
319 Vitros Anti-SARS-CoV-2 IgG test accounted for approximately 27% of IC_{50} variance. Since the
320 format of the LFA reports decreasing density values as neutralization increases, LFA was
321 significantly inversely correlated with IC_{50} values ($r = -0.720$, $p < 0.001$), while Ortho Vitros Anti-
322 SARS-CoV-2 IgG test values showed a significant positive correlation to IC_{50} values ($r = 0.522$, p
323 $= 0.001$). Additionally, LFA and Ortho Vitros Anti-SARS-CoV-2 IgG test values showed a
324 significant relationship with each other ($r = -0.572$, $p < 0.001$).

325 To evaluate bias between the assays, mean differences and 95% confidence intervals
326 (CIs) were calculated and plotted alongside limits of agreement (**Figure 5**). Both LFA and Ortho
327 Vitros Anti-SARS-CoV-2 IgG test values showed high agreement with titer, although Ortho Vitros
328 Anti-SARS-CoV-2 IgG test showed a tendency to underestimate neutralizing capacity while the
329 LFA method showed no bias.
330



331
332 **Figure 5.** Bland-Altman plots showing bias (mean difference and 95% CI) and computed limits
333 of agreement (mean difference \pm 2SD) between **(A)** Ortho Vitros Anti-SARS-CoV-2 IgG test and
334 IC₅₀ values and **(B)** our LFA and IC₅₀ values. Thirty-eight samples were tested.
335

336 Univariate ROC analysis was performed to assess the performance of the newly
337 developed LFA and Ortho assay to classify non-neutralizing (Neg—1:160), and neutralizing
338 groups (\geq 1:320) (**Figure 6**). As can be seen in **Figure 6B** and **6D**, the LFA misclassified one non-
339 neutralizing sample (Neg—1:160) as neutralizing (\geq 1:320). In contrast, Ortho Vitros Anti-SARS-
340 CoV-2 IgG test misclassified that same non-neutralizing sample as neutralizing, in addition to
341 incorrectly classifying five additional neutralizing samples as non-neutralizing. Importantly, our
342 LFA method exhibited a greater dynamic range of differential values as compared to Ortho's test.
343 (**Figure 5**), translating to superior classification accuracy of the LFA method in detecting
344 neutralizing samples (titer \geq 1:320) compared to Ortho Vitros Anti-SARS-CoV-2 IgG test (**Figures**
345 **6A** and **6C**).
346



347

348 **Figure 6. (A)** Univariate ROC analysis of Ortho Vitros Anti-SARS-CoV-2 IgG test for
349 discrimination of neutralizing samples ($\geq 1:320$) [AUC: 0.856, 95% CI: 0.697—0.953, sensitivity =
350 0.7, specificity = 0.9]. **(B)** Box plot of Ortho Vitros Anti-SARS-CoV-2 IgG test values between
351 neutralizing ($\geq 1:320$) and non-neutralizing (Neg—1:160) groups. **(C)** Univariate ROC analysis of
352 LFA for discrimination of neutralizing samples ($\geq 1:320$) [AUC: 0.978, 95% CI: 0.908—1.0,
353 sensitivity = 1.0, specificity = 0.9]. **(D)** Box plot of LFA values between neutralizing ($\geq 1:320$) and
354 non-neutralizing (Neg—1:160) groups.

355

356

357

358 Our LFA showed high accuracy for classification of neutralizing samples (AUC = 0.978),
359 while the Ortho Vitros Anti-SARS-CoV-2 IgG test showed modest accuracy for classification of
360 neutralizing samples (AUC = 0.856). Furthermore, while the LFA method showed a narrow
361 confidence interval (95% CI: 0.908—1.00), ROC analysis of Ortho Vitros Anti-SARS-CoV-2 IgG
362 test values showed a wider range (95% CI: 0.697—0.953), indicating less certainty. Notably, while
both methods showed roughly 90% specificity, Ortho Vitros Anti-SARS-CoV-2 IgG test Vitros Anti-

363 SARS-CoV-2 IgG test showed only 70% sensitivity. In contrast, the novel LFA method showed
364 perfect sensitivity (100%) in this analysis of 38 samples.

365 Optimal cutoffs were computed to maximize AUC. For the LFA, density unit values below
366 263,000 classify samples as neutralizing and correspond to titers $\geq 1:320$. Density unit values
367 above this LFA cutoff classify samples in the non-neutralizing group. For the Ortho Vitros Anti-
368 SARS-CoV-2 IgG test, values between 0 and 23.3 were representative of non-neutralizing
369 capacity, whereas values above 23.3 were reflective of the neutralizing group. If we used the
370 FDA cutoff of 12 instead of the 23.3 value calculated using our results, AUC would be reduced to
371 0.69 (sensitivity = 0.55, specificity = 0.83).

372 Polyclonal antisera was used in this study, not an individual Mab, so the limit of detection
373 (LoD) does not exactly apply). However, we can calculate the LoD by line density based on the
374 method of Armbruster and Pry(26) as the highest line density from samples still containing
375 neutralizing antibodies and distinguishable from blank except that the operand sign was changed
376 because due to the competitive format of the LFA: $LoD = \text{limit of blank (LoB)} - (1.65 * SD_{\text{low conc}}$
377 $_{\text{sample}})$: $LoD = 1,047,382 - (1.65 * 63,769) = 942,481$ Test Line Density Units. The average line
378 density observed for the top 10 donors who demonstrated the strongest ability to prevent RBD
379 from binding to ACE2 was 20,706.

380 The principle of infusing convalescent plasma from recovered individuals into patients
381 fighting COVID-19 is to transfer NABs from the donor to the recipient, as has been done for
382 several other diseases(27–29). The rapid test described here, could quickly and efficiently
383 classify COVID-19 convalescent plasma (CCP) units so that the sickest patients might receive
384 the most potently neutralizing plasma. Although levels of neutralizing antibody to achieve in
385 patients receiving CCP remains undefined, our point-of-care test might be useful at the bedside
386 to monitor a patient receiving highly neutralizing CCP as he/she begins to demonstrate NABs in
387 circulation, as shown in **Figure 7A**. It could help in deciding whether to administer another unit

388 of highly neutralizing CCP to a patient fighting COVID19. The same scenario might also be
389 applied to hyperimmune gammaglobulin or neutralizing monoclonal antibody infusion.

390 To demonstrate the utility of our LFA to measure NAbs in whole blood, we used a lateral
391 flow strip with a blood filter and performed an experiment in which a neutralizing monoclonal
392 antibody based on the B-38(20) sequence was titrated into whole blood as shown in **Figure 7B**.
393 Density units were not obtained in these experiments but both **Figures 7A** and **7B** demonstrate
394 the semi-quantitative nature of this test to visually distinguish different levels of NAbs in plasma
395 and whole blood.

396

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

418

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

440




Figure 7. (A) Highly neutralizing plasma from an individual recovered from COVID-19 (M21) converts non-immune human plasma (ND82) into highly neutralizing plasma; 10 μ l of plasma was added to each lateral flow cassette. Text below each lateral flow cassette indicates the percent M21 and percent ND82 plasma used to run the lateral flow test. **(B)** Titration of anti-RBD neutralizing mAb into 10 μ l of heparinized whole blood. For both types of cassettes, plasma or blood sample was immediately chased with 50 μ l sample buffer. Densities were read and cassettes were imaged after 10 minutes development.

Discussion

Serologic tests that detect responses to infection are an important population surveillance tool during pandemics because they provide data on pathogen exposure, especially

441 when a subset of the population is asymptomatic and would not have been diagnosed by
442 molecular methods(30, 31). While over 90% of individuals diagnosed with COVID-19 generate
443 antibody responses(30) we are only beginning to learn about the prevalence and duration of
444 NABs induced by a natural infection. This lack of knowledge is mainly due to the fact that virus-
445 based neutralization assays require *i)* BSL2 or BSL3 facilities, *ii)* highly skilled personnel, *iii)*
446 permissive cells and quantified virus, and *iv)* take longer than 24 hours to obtain results. Since
447 every viral vaccine, including COVID-19 vaccines, administered to humans is designed to elicit
448 antibodies that neutralize virus by blocking host cell infection, development of NABs is a
449 hallmark of protection from disease. Therefore, there is a need for rapid, accurate tests that
450 measure levels of NABs. Furthermore, in a post-vaccine world, longitudinal measurement of
451 protective, neutralizing antibodies is crucial. Measurement of anti-viral T cells also indicates that
452 infected individuals could destroy infected host cells if virus escapes neutralization.

453 We developed a rapid, 10-minute lateral flow test that measures levels of NABs in serum
454 and plasma. As shown in **Figure 2**, the lateral flow test correlates well with serologic titers
455 determined using a VSV-based pseudotype assay, and IC₅₀ values in an authentic SARS-CoV-2
456 microneutralization assay, especially when serum sample titers are ≥640 and IC₅₀ values
457 are >250. Samples with less potent NABs in both viral assays correlated with decreased ability
458 to block RBD from binding to ACE2 in the LFAs.

459 The LFA and Ortho Vitros Anti-SARS-CoV-2 IgG test methods showed a strong,
460 significant correlation with each other ($r = -0.572$, $p < 0.001$), displaying an appreciable degree of
461 linear relation ($r = -0.720$, $p < 0.001$)(32). Importantly, LFA accounts for 52% of observed IC₅₀
462 variance ($R^2 = 0.5187$) while, in comparison, Ortho Vitros Anti-SARS-CoV-2 IgG test accounts for
463 27% ($R^2 = 0.2725$). Although absolute quantitation of a construct demands an excellent coefficient
464 of determination ($R^2 \geq 0.99$)(33), variables with $R^2 \geq 0.5$ are highly predictive in univariate
465 regression models while measures with $R^2 < 0.5$ are recommended for use in multivariate models
466 in combination with complementary measures to increase predictive accuracy(34, 35).

467 Additionally, Bland-Altman analysis (**Figure 5**) showed the Ortho Vitros Anti-SARS-CoV-2 IgG
468 test to be prone to underestimation of IC₅₀ values. In contrast, the LFA method did not exhibit any
469 over- or underestimation bias. Furthermore, across mean values for both methods, LFA showed
470 discrete differential values while Ortho Vitros Anti-SARS-CoV-2 IgG test struggled to differentiate
471 samples with high neutralizing capacity (IC₅₀ values).

472

473 Since the Ortho Vitros Anti-SARS-CoV-2 IgG test uses S1, which includes RBD, it is
474 likely that antibodies reactive with other parts of S1—even some that may neutralize via N-
475 terminal domain—are responsible for increased reactivity to S1 when they are not neutralizing in
476 our RBD-ACE2 competition assay. Advantages of our POC test is that it can be inexpensively
477 and rapidly deployed in studies to determine levels of NABs that protect against re-infection and
478 limit transmission of the virus. Moreover, rapid inexpensive tests can be used longitudinally to
479 evaluate duration of protective immunity in both naturally infected and many more vaccinated
480 individuals than could ever be evaluated using BSL2 or BSL3-based neutralization assays.

481

482 In the setting of much debated CCP, a rapid test could be used to measure levels of
483 NABs in a CCP product prior to infusion, or potential donors who recovered from COVID-19.
484 During infusion of CCP, a rapid test could be used to help decide if a patient fighting COVID-19
485 requires another unit of highly neutralizing plasma. If a particular donor's CCP has very high
486 levels of CCP, patients might need only one unit. On the other hand, if donor CCP contains
487 moderate levels of NABs, the patient may require multiple units to achieve therapeutic levels of
488 NABs. However, since we do not know what an adequate therapeutic dose of NABs is, this
489 rapid test could be a valuable tool in trials to determine under what conditions CCP,
490 hyperimmune globulin, and neutralizing mAbs are effective therapeutic agents for COVID19
491 patients.

492

493 Limitations of the LFA are that it uses only the RBD portion of SARS-CoV-2 spike
494 protein. Although the vast majority of reports indicate that the principle neutralizing domain is
495 RBD portion of spike protein, mAbs have been reported that neutralize SARS-CoV-2 by binding
496 to the N-terminal domain of spike protein(36, 37). Also, since the spike protein assumes several
497 conformations during viral binding and entry(38), neutralizing epitopes exist on the quaternary
498 structure of spike(37). Although RBDs on the nanoparticles may associate, it is unlikely they
499 assume a native quaternary conformation.

500 Other limitations are the binary nature of the data analysis (neutralizing and non-
501 neutralizing) of a continuous assay. Clearly, line densities demonstrate moderate levels of
502 neutralization. Since blood draws and subsequent assays are a “snapshot in time” of
503 neutralizing antibody activity, levels were undoubtedly increasing in some patients and
504 decreasing in others. LFAs are generally inexpensive and highly portable compared to other
505 laboratory-based tests, so neutralizing antibody levels could be measured using the LFA to
506 longitudinally assess protective neutralizing antibody immunity. Another limitation is that the
507 LFA does not differentiate high affinity anti-RBD NABs from an abundance of lower affinity anti-
508 RBD NABs. In related experiments, we have observed patient sera that bind strongly to RBD,
509 but do not demonstrate neutralizing activity (data not shown).

510 This test may prove very useful in monitoring COVID-19 vaccine recipients. Although
511 vaccines have now been approved for distribution and administration, durability of protective
512 immunity elicited by any COVID-19 vaccine is unknown. It is the goal of all COVID-19 vaccines
513 to induce protective NABs. However, since clinical trials of vaccines have enrolled 30,000 to
514 60,000 participants, it is not logistically possible to draw a tube of blood from each vaccine
515 recipient longitudinally to determine duration of protective NABs. Application of our test in
516 vaccine recipients using a drop of blood obtained from a finger-stick as shown in **Figure 7B**
517 might lead to more comprehensive longitudinal monitoring of increases and decreases in
518 protective humoral immunity.

519

520 **Data availability**

521 The authors declare that data supporting the findings of this study are available within the
522 paper. Additional data mentioned but not shown are available from the corresponding author
523 upon reasonable request.

524

525 **References**

- 526 1. Ghinai I, McPherson TD, Hunter JC, Kirking HL, Christiansen D, Joshi K, Rubin R, Morales-Estrada S,
527 Black SR, Pacilli M, Fricchione MJ, Chugh RK, Walblay KA, Ahmed NS, Stoecker WC, Hasan NF,
528 Burdsall DP, Reese HE, Wallace M, Wang C, Moeller D, Korpics J, Novosad SA, Benowitz I, Jacobs
529 MW, Dasari VS, Patel MT, Kauerauf J, Charles EM, Ezike NO, Chu V, Midgley CM, Rolfes MA, Gerber
530 SI, Lu X, Lindstrom S, Verani JR, Layden JE, Brister S, Goldesberry K, Hoferka S, Jovanov D, Nims D,
531 Saathoff-Huber L, Hoskin Snelling C, Adil H, Ali R, Andreychak E, Bemis K, Frias M, Quartey-
532 Kumapley P, Baskerville K, Murphy E, Murskyj E, Noffsinger Z, Vercillo J, Elliott A, Onwuta US, Burck
533 D, Abedi G, Burke RM, Fagan R, Farrar J, Fry AM, Hall AJ, Haynes A, Hoff C, Kamili S, Killerby ME,
534 Kim L, Kujawski SA, Kuhar DT, Lynch B, Malapati L, Marlow M, Murray JR, Rha B, Sakthivel SKK,
535 Smith-Jeffcoat SE, Soda E, Wang L, Whitaker BL, Uyeki TM. 2020. First known person-to-person
536 transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the USA. The
537 Lancet 395:1137–1144.
- 538 2. Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, Zhang L, Fan G, Xu J, Gu X, Cheng Z, Yu T, Xia J, Wei Y, Wu
539 W, Xie X, Yin W, Li H, Liu M, Xiao Y, Gao H, Guo L, Xie J, Wang G, Jiang R, Gao Z, Jin Q, Wang J, Cao
540 B. 2020. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The
541 Lancet 395:497–506.

- 542 3. Li R, Pei S, Chen B, Song Y, Zhang T, Yang W, Shaman J. 2020. Substantial undocumented infection
543 facilitates the rapid dissemination of novel coronavirus (SARS-CoV-2). *Science* 368:489–493.
- 544 4. Widge AT, Roupael NG, Jackson LA, Anderson EJ, Roberts PC, Makhene M, Chappell JD, Denison
545 MR, Stevens LJ, Pruijssers AJ, McDermott AB, Flach B, Lin BC, Doria-Rose NA, O’Dell S, Schmidt SD,
546 Neuzil KM, Bennett H, Leav B, Makowski M, Albert J, Cross K, Edara V-V, Floyd K, Suthar MS,
547 Buchanan W, Luke CJ, Ledgerwood JE, Mascola JR, Graham BS, Beigel JH. 2020. Durability of
548 Responses after SARS-CoV-2 mRNA-1273 Vaccination. *N Engl J Med* 4.
- 549 5. Loeffelholz MJ, Tang Y-W. 2020. Laboratory diagnosis of emerging human coronavirus infections –
550 the state of the art. *Emerg Microbes Infect* 9:747–756.
- 551 6. Yongchen Z, Shen H, Wang X, Shi X, Li Y, Yan J, Chen Y, Gu B. 2020. Different longitudinal patterns of
552 nucleic acid and serology testing results based on disease severity of COVID-19 patients. *Emerg*
553 *Microbes Infect* 9:833–836.
- 554 7. McAndrews KM, Dowlatshahi DP, Hensel J, Ostrosky-Zeichner LL, Papanna R, LeBleu VS, Kalluri R.
555 2020. Identification of IgG antibody response to SARS-CoV-2 spike protein and its receptor binding
556 domain does not predict rapid recovery from COVID-19. preprint, *Infectious Diseases (except*
557 *HIV/AIDS)*.
- 558 8. Han Z, Battaglia F, Terlecky SR. 2020. Discharged COVID-19 Patients Testing Positive Again for SARS-
559 CoV-2 RNA: A Minireview of Published Studies from China. *J Med Virol* jmv.26250.
- 560 9. Ye G, Pan Z, Pan Y, Deng Q, Chen L, Li J, Li Y, Wang X. 2020. Clinical characteristics of severe acute
561 respiratory syndrome coronavirus 2 reactivation. *J Infect* 80:e14–e17.

- 562 10. Hoang VT, Dao TL, Gautret P. 2020. Recurrence of positive SARS-CoV-2 in patients recovered from
563 COVID-19. *J Med Virol* jmv.26056.
- 564 11. Robbiani DF, Gaebler C, Muecksch F, Lorenzi JCC, Wang Z, Cho A, Agudelo M, Barnes CO, Gazumyan
565 A, Finkin S, Hagglof T, Oliveira TY, Viant C, Hurley A, Hoffmann H-H, Millard KG, Kost RG, Cipolla M,
566 Gordon K, Bianchini F, Chen ST, Ramos V, Patel R, Dizon J, Shimeliovich I, Mendoza P, Hartweger H,
567 Nogueira L, Pack M, Horowitz J, Schmidt F, Weisblum Y, Michailidis E, Ashbrook AW, Waltari E, Pak
568 JE, Huey-Tubman KE, Koranda N, Hoffman PR, West AP, Rice CM, Hatzioannou T, Bjorkman PJ,
569 Bieniasz PD, Caskey M, Nussenzweig MC. 2020. Convergent Antibody Responses to SARS-CoV-2
570 Infection in Convalescent Individuals. preprint, *Immunology*.
- 571 12. Juno JA, Tan H-X, Lee WS, Reynaldi A, Kelly HG, Wragg K, Esterbauer R, Kent HE, Batten CJ, Mordant
572 FL, Gherardin NA, Pymm P, Dietrich MH, Scott NE, Tham W-H, Godfrey DI, Subbarao K, Davenport
573 MP, Kent SJ, Wheatley AK. 2020. Immunogenic profile of SARS-CoV-2 spike in individuals recovered
574 from COVID-19. preprint, *Infectious Diseases (except HIV/AIDS)*.
- 575 13. Wu F, Wang A, Liu M, Wang Q, Chen J, Xia S, Ling Y, Zhang Y, Xun J, Lu L, Jiang S, Lu H, Wen Y, Huang
576 J. 2020. Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort
577 and their implications. *MedRxiv Prepr* 20.
- 578 14. Vandergaast R, Carey T, Reiter S, Lech P, Gnanadurai C, Tesfay M, Buehler J, Suksanpaisan L, Naik S,
579 Brunton B, Recker J, Haselton M, Ziegler C, Roesler A, Mills JR, Theel E, Weaver SC, Rafael G,
580 Roforth MM, Jerde C, Tran S, Diaz RM, Bexon A, Baum A, Kyratsous CA, Peng KW, Russell SJ. 2020.
581 Development and validation of IMMUNO-COV™: a high-throughput clinical assay for detecting
582 antibodies that neutralize SARS-CoV-2. preprint, *Immunology*.

- 583 15. Crawford KHD, Eguia R, Dingens AS, Loes AN, Malone KD, Wolf CR, Chu HY, Tortorici MA, Veessler D,
584 Murphy M, Pettie D, King NP, Balazs AB, Bloom JD. 2020. Protocol and reagents for pseudotyping
585 lentiviral particles with SARS-CoV-2 Spike protein for neutralization assays. preprint, Microbiology.
- 586 16. Wang Q, Zhang Y, Wu L, Niu S, Song C, Zhang Z, Lu G, Qiao C, Hu Y, Yuen K-Y, Wang Q, Zhou H, Yan J,
587 Qi J. 2020. Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2. Cell
588 S009286742030338X.
- 589 17. Premkumar L, Segovia-Chumbez B, Jadi R, Martinez DR, Raut R, Markmann A, Cornaby C, Bartelt L,
590 Weiss S, Park Y, Edwards CE, Weimer E, Scherer EM, Roupheal N, Edupuganti S, Weiskopf D, Tse
591 LV, Hou YJ, Margolis D, Sette A, Collins MH, Schmitz J, Baric RS, de Silva AM. 2020. The receptor
592 binding domain of the viral spike protein is an immunodominant and highly specific target of
593 antibodies in SARS-CoV-2 patients. Sci Immunol 5:eabc8413.
- 594 18. Tan CW, Chia WN, Qin X, Liu P, Chen MI-C, Tiu C, Hu Z, Chen VC-W, Young BE, Sia WR, Tan Y-J, Foo R,
595 Yi Y, Lye DC, Anderson DE, Wang L-F. 2020. A SARS-CoV-2 surrogate virus neutralization test based
596 on antibody-mediated blockage of ACE2–spike protein–protein interaction. Nat Biotechnol
597 <https://doi.org/10.1038/s41587-020-0631-z>.
- 598 19. Hanson QM, Wilson KM, Shen M, Itkin Z, Eastman RT, Shinn P, Hall MD. 2020. Targeting ACE2-RBD
599 interaction as a platform for COVID19 therapeutics: Development and drug repurposing screen of
600 an AlphaLISA proximity assay. preprint, Biochemistry.
- 601 20. Wu Y, Wang F, Shen C, Peng W, Li D, Zhao C, Li Z, Li S, Bi Y, Yang Y, Gong Y, Xiao H, Fan Z, Tan S, Wu
602 G, Tan W, Lu X, Fan C, Wang Q, Liu Y, Zhang C, Qi J, Gao GF, Gao F, Liu L. 2020. A noncompeting
603 pair of human neutralizing antibodies block COVID-19 virus binding to its receptor ACE2. Science
604 368:1274–1278.

- 605 21. Davide Giavarina. 2015. Understanding Bland Altman analysis. *Biochem Medica* 25:141–151.
- 606 22. Doğan NÖ. 2018. Bland-Altman analysis: A paradigm to understand correlation and agreement. *Turk*
607 *J Emerg Med* 18:139–141.
- 608 23. Obuchowski NA, Bullen JA. 2018. Receiver operating characteristic (ROC) curves: review of methods
609 with applications in diagnostic medicine. *Phys Med Biol* 29.
- 610 24. Nakas CT, Yannoutsos CT. November 30. Ordered multiple-class ROC analysis with continuous
611 measurements. *Med Stat* 23:3437–49.
- 612 25. Xie X, Muruato A, Lokugamage KG, Narayanan K, Zhang X, Zou J, Liu J, Schindewolf C, Bopp NE,
613 Aguilar PV, Plante KS, Weaver SC, Makino S, LeDuc JW, Menachery VD, Shi P-Y. 2020. An Infectious
614 cDNA Clone of SARS-CoV-2. *Cell Host Microbe* 27:841-848.e3.
- 615 26. Armbruster DA, Pry T. Limit of Blank, Limit of Detection and Limit of Quantitation. 2008 *Clin*
616 *Biochem Rev* 29:s50.
- 617 27. Leider JP, Brunker PAR, Ness PM. 2010. Convalescent transfusion for pandemic influenza: preparing
618 blood banks for a new plasma product?: CONVALESCENT TRANSFUSION FOR PANDEMIC
619 INFLUENZA. *Transfusion (Paris)* 50:1384–1398.
- 620 28. Yeh K-M, Chiueh T-S, Siu LK, Lin J-C, Chan PKS, Peng M-Y, Wan H-L, Chen J-H, Hu B-S, Perng C-L, Lu J-
621 J, Chang F-Y. 2005. Experience of using convalescent plasma for severe acute respiratory syndrome
622 among healthcare workers in a Taiwan hospital. *J Antimicrob Chemother* 56:919–922.
- 623 29. Enria D, Briggiler A, Fernandez N, Levis S, Maiztegui J. 1984. Importance of dose of neutralising
624 antibodies in treatment of Argentine Haemorrhagic Fever with immune plasma. *The Lancet* 255–
625 256.

- 626 30. Gudbjartsson DF, Norddahl GL, Melsted P, Gunnarsdottir K, Holm H, Eythorsson E, Arnthorsson AO,
627 Helgason D, Bjarnadottir K, Ingvarsson RF, Thorsteinsdottir B, Kristjansdottir S, Birgisdottir K,
628 Kristinsdottir AM, Sigurdsson MI, Arnadottir GA, Ivarsdottir EV, Andresdottir M, Jonsson F,
629 Agustsdottir AB, Berglund J, Eiriksdottir B, Fridriksdottir R, Gardarsdottir EE, Gottfredsson M,
630 Gretarsdottir OS, Gudmundsdottir S, Gudmundsson KR, Gunnarsdottir TR, Gylfason A, Helgason A,
631 Jensson BO, Jonasdottir A, Jonsson H, Kristjansson T, Kristinsson KG, Magnúsdottir DN, Magnússon
632 OT, Olafsdottir LB, Rognvaldsson S, le Roux L, Sigmundsdottir G, Sigurdsson A, Sveinbjornsson G,
633 Sveinsdottir KE, Sveinsdottir M, Thorarensen EA, Thorbjornsson B, Thordardottir M,
634 Saemundsdottir J, Kristjansson SH, Josefsdottir KS, Masson G, Georgsson G, Kristjansson M, Moller
635 A, Palsson R, Gudnason T, Thorsteinsdottir U, Jonsdottir I, Sulem P, Stefansson K. 2020. Humoral
636 Immune Response to SARS-CoV-2 in Iceland. *N Engl J Med* NEJMoa2026116.
- 637 31. Lee S, Kim T, Lee E, Lee C, Kim H, Rhee H, Park SY, Son H-J, Yu S, Park JW, Choo EJ, Park S, Loeb M,
638 Kim TH. 2020. Clinical Course and Molecular Viral Shedding Among Asymptomatic and
639 Symptomatic Patients With SARS-CoV-2 Infection in a Community Treatment Center in the
640 Republic of Korea. *JAMA Intern Med* <https://doi.org/10.1001/jamainternmed.2020.3862>.
- 641 32. Schober P, Boer C, Schwarte LA. 2018. Correlation Coefficients: Appropriate Use and Interpretation.
642 *Anesth Analg* 126:1763–1768.
- 643 33. Rights JD, Sterba SK. Quantifying explained variance in multilevel models: An integrative framework
644 for defining R-squared measures. *Psychol Methods* 24:309–338.
- 645 34. Rights JD, Sterba SK. A framework of R-squared measures for single-level and multilevel regression
646 mixture models. *Psychol Methods* 23:434–457.

- 647 35. Rights JD, Sterba SK. New Recommendations on the Use of R-Squared Differences in Multilevel
648 Model Comparisons. *Multivar Behav Res* 55:568–599.
- 649 36. Chi X, Yan R, Zhang J, Zhang G, Zhang Y, Hao M, Zhang Z, Fan P, Dong Y, Yang Y, Chen Z, Guo Y, Zhang
650 J, Li Y, Song X, Chen Y, Xia L, Fu L, Hou L, Xu J, Yu C, Li J, Zhou Q, Chen W. 2020. A neutralizing
651 human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. *Science*
652 eabc6952.
- 653 37. Liu L, Wang P, Nair MS, Yu J, Rapp M, Wang Q, Luo Y, Chan JF-W, Sahi V, Figueroa A, Guo XV, Cerutti
654 G, Bimela J, Gorman J, Zhou T, Chen Z, Yuen K-Y, Kwong PD, Sodroski JG, Yin MT, Sheng Z, Huang Y,
655 Shapiro L, Ho DD. 2020. Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2
656 spike. *Nature* 584:450–456.
- 657 38. Cai Y, Zhang J, Xiao T, Peng H, Sterling SM, Walsh RM, Rawson S, Rits-Volloch S, Chen B. 2020.
658 Distinct conformational states of SARS-CoV-2 spike protein. *Science* eabd4251.
- 659
660
661
662
663
664
665

666
667
668

669
670
671